



Recent Advances in Pancreatic Neoplasms: Part II

Guest Editors:

Dr. Cosimo Sperti

Department of Surgery, Oncology
and Gastroenterology,
Hepatobiliary and Pancreatic
Surgery Unit, University of Padua,
Padua, Italy

Dr. Domenico Bassi

Department of Surgery, Oncology
and Gastroenterology-DISCOG,
University of Padua, Padua, Italy

Dr. Simone Serafini

Department of Surgery, Oncology
and Gastroenterology-DISCOG,
University of Padua, Padua, Italy

Deadline for manuscript
submissions:

closed (20 September 2023)

Message from the Guest Editors

It is our pleasure to invite you and members of your research group to submit an article for a Special Issue titled "Recent Advances in Pancreatic Neoplasms: Part II". This volume follows on from the previous one, in which 14 papers were published.

Pancreatic cancer is the fourth leading cause of cancer death in Western countries, and will soon become the second leading cause of gastrointestinal cancer death. Surgery and adjuvant therapy remains the standard treatment, but the recurrence rate remains high. Multimodality treatment, that is, neoadjuvant therapy and a combination of chemotherapy, radiotherapy, immunotherapy, and surgery, appears to be essential to obtain better results, but definitive conclusions on its effectiveness are lacking. This Special Issue is focused on the latest developments and challenges in multimodality therapy for resectable and locally advanced pancreatic tumors, the search for prognostic factors for early and late outcomes after therapy, and the evaluation of novel strategies for individualized treatment. We invite relevant original research, systematic reviews, meta-analyses, and short communications covering the above-mentioned topics.





an Open Access Journal by MDPI

Editors-in-Chief

Prof. Dr. Emmanuel Andrès

Internal Medicine Department,
University Hospital Strasbourg,
67000 Strasbourg, France

Prof. Dr. Kent Doi

Department of Emergency and
Critical Care Medicine, University
of Tokyo, Tokyo 113-8655, Japan

Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's (JCM)* staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)

Contact Us

Journal of Clinical Medicine Editorial
Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jcm
jcm@mdpi.com
[X@JCM_MDPI](https://twitter.com/JCM_MDPI)